New MRC grant awarded
A new MRC grant entitled Treatment of osteoarthritis by inhibition of aggrecanases using targeted delivery of engineered TIMP-3 has been awarded. This Medical Research Council-funded project is a collaboration between Prof. Andrew Pitsillides (RVC), (University of East Anglia) and is led by , Brighton and Sussex Medical School.
The project seeks to harness the chondroprotective properties of a natural inhibitor of aggrecanases, named TIMP3, to protect against osteoarthritis. It will employ a novel method of delivering a genetically-modified form of TIMP3, which will have greater specificity capable of targeting its activity only to sites of disease, thus eliminating possible side-effects and increasing its therapeutic efficacy.
You may also be interested in:
-
RVC research highlights the potential gains from early conversations and treatment for newly diagnosed cats with diabetes
New research from the ÌÇÐÄvlogÊÓƵ (RVC) has shed new light on the epidemiology, risk …